Therapeutic Window

Key Questions Regarding The Therapeutic Window of ADCs

by
Key Questions Regarding The Therapeutic Window of ADCs

Introduction Antibody-drug conjugate (ADC) therapy has rapidly developed over the past few decades, with 14 products approved globally and over 140 ADCs currently in clinical trials. By 2030, the ADC market is expected to exceed $15 billion. The basic principle of ADCs: by combining the specificity of monoclonal antibodies with the cytotoxicity of effective small … Read more

New Pathway for ADCs – Dual Payload ADCs

by
New Pathway for ADCs - Dual Payload ADCs

Currently, all marketed ADC drug molecules use a single small molecule toxin as the effective payload, but challenges such as drug resistance and limited therapeutic effects still exist. Therefore, clinical chemotherapy regimens often employ combinations of multiple drugs for combination therapy. Considering the clinical efficacy of combination chemotherapy, ADC drugs with two or more effective … Read more